LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

CPT copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. CMS has approved Second Sight ...

Second Sight Medical Products shares trade more than 400% higher after the company reported that the FDA granted approval for its Argus 2s Retinal Prosthesis System designed to deliver useful ...

Shares of Second Sight Medical Products Inc. soared 104.2% on heavy volume in midday trading Monday, bringing its two-day gain to 728.7%, after the Food and Drug Administration approved the company's ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Second Sight Medical shares jumped to nearly $10 after the FDA approved its Argus2 Retinal Prosthesis System. The regulatory approval arrives as Second Sight works to complete a business combination ...

The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

For more on June 24th's medical story, regarding the woman who lost her vision but is regaining her sight thanks to the system, visit http://www.2-sight.eu/en/product ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...